{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:17:53Z","timestamp":1789823873979,"version":"4.0.1"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council (NHMRC) Principal Research Fellowships"},{"name":"ARC Future Fellowship","award":["FT100100321"],"award-info":[{"award-number":["FT100100321"]}]}],"content-domain":{"domain":["drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.drugalcdep.2013.12.005","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T00:15:18Z","timestamp":1389140118000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["The diversion and injection of a buprenorphine-naloxone soluble film formulation"],"prefix":"10.1016","volume":"136","author":[{"given":"Briony","family":"Larance","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mattick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0005","series-title":"National Opioid Pharmacotherapy Statistics Annual Data collection: 2011 report. Cat. no. HSE 161","author":"Australian Institute of Health and Welfare","year":"2012"},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0010","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.drugalcdep.2009.08.011","article-title":"Monitoring risk: post marketing surveillance and signal detection","volume":"105","author":"Dart","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5694\/j.1326-5377.2009.tb02729.x","article-title":"Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist\u2013antagonist formulation","volume":"191","author":"Degenhardt","year":"2009","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0020","series-title":"Methadone Diversion: Experiences and Issues. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse. DHEW Publication No. (ADM) 77-488","author":"Inciardi","year":"1977"},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2011.04.002","article-title":"Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing","volume":"118","author":"Larance","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugalcdep.2012.12.009","article-title":"A randomised controlled trial of sublingual buprenorphine\u2013naloxone film versus tablets in the management of opioid dependence","volume":"131","author":"Lintzeris","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0035","series-title":"Investigation of Methadone Dosing in Victoria: Factors Influencing Dosing Levels","author":"Lintzeris","year":"2007"},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0040","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.drugalcdep.2009.08.003","article-title":"Case histories in pharmaceutical risk management","volume":"105","author":"McCormick","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0045","series-title":"Treatment with SUBOXONE Film: Understanding the benefits","author":"Reckitt Benckiser Inc.","year":"2013"},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0050","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1517\/17425247.2012.729574","article-title":"Buprenorphine and buprenorphine\/naloxone soluble-film for treatment of opioid dependence","volume":"9","author":"Soyka","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0055","series-title":"Australian Drug Trends 2011. Findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trends Series No. 73","author":"Stafford","year":"2012"},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0060","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/09687630701425865","article-title":"Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence","volume":"15","author":"Winstock","year":"2008","journal-title":"Drug Educ. Prev. Policy"},{"key":"10.1016\/j.drugalcdep.2013.12.005_bib0065","series-title":"WHO Model List of Essential Medicines","author":"World Health Organization","year":"2013"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871613005218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871613005218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T10:01:21Z","timestamp":1597312881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871613005218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":13,"alternative-id":["S0376871613005218"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.12.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718240407.793489674","asserted-by":"object"}]},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The diversion and injection of a buprenorphine-naloxone soluble film formulation","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}